Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training (HyperLa)
20 juli 2026 bijgewerkt door: Prof. Dr. Henning Wackerhage, Technical University of Munich
HyperLa: Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training: A Multi-centre Study by the HyperLa Study Group
The HyperLa study investigates whether a person's "glycolyticness"-the efficiency with which their body uses glycolysis for energy-can predict how much their muscles will grow (hypertrophy) in response to resistance training.
Participants will undergo a specialized "vLapeak" test, which measures the maximal rate of lactate accumulation during a 10-second all-out cycling sprint, to determine their individual glycolytic power.
Following this initial assessment, participants will complete eight weeks of standardized, twice-weekly resistance training focused on the lower body.
The study aims to determine if individuals with higher initial vLapeak values experience greater increases in muscle size compared to those with lower values.
This research may help explain why people respond differently to exercise and support the development of personalized training programs.
Studie Overzicht
Toestand
Werving
Interventie / Behandeling
Gedetailleerde beschrijving
This multicentre, prospective, single-arm interventional cohort study aims to link metabolic phenotypes with physical adaptations.
- Primary Assessment: Glycolytic power is quantified via the vLapeak test, defined as the peak rate of blood lactate accumulation during a 10-second isokinetic or sprint-configured cycle ergometry test.
- Intervention: The 8-week resistance training program consists of two supervised sessions per week. Exercises include the leg press (or Smith-machine squat) and leg extensions, performed for 4 sets of 8-12 repetitions. Intensity progresses from an RPE of 6 to voluntary muscular failure by the third week.
- Measurements: Muscle hypertrophy is primarily assessed via ultrasound measurement of muscle thickness and cross-sectional area (CSA) of the thigh muscles before and after the intervention.
- Secondary Objectives: The study also evaluates changes in the plasma metabolome via venous blood samples and, at select sites, analyzes muscle biopsies for glycolytic enzyme activity and fiber type composition to further validate the vLapeak results.
Studietype
Ingrijpend
Inschrijving (Geschat)
120
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Henning Wackerhage, Prof. Dr.
- Telefoonnummer: +49 89 289 24480
- E-mail: henning.wackerhage@tum.de
Studie Contact Back-up
- Naam: Lara Becker
- E-mail: lara.becker@tum.de
Studie Locaties
-
-
Bavaria
-
München, Bavaria, Duitsland, 80809
- Werving
- Technical University of Munich, TUM School of Medicine and Health
-
Contact:
- Henning Wackerhage, Prof. Dr.
- Telefoonnummer: +49 89 289 24480
- E-mail: henning.wackerhage@tum.de
-
Contact:
- Lara Becker
- E-mail: lara.becker@tum.de
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Duitsland, 51147
- Werving
- DLR Cologne, Department of Metabolism and Human Performance
-
Contact:
- Dominik Pesta, Prof. Dr.
- Telefoonnummer: +49 2203 601 2028
- E-mail: dominik.pesta@dlr.de
-
Düsseldorf, North Rhine-Westphalia, Duitsland, 40233
- Werving
- iST University of Applied Sciences
-
Contact:
- Stephan Geisler, Prof.Dr.
- Telefoonnummer: +49 211 86668 6104
- E-mail: sgeisler@ist-hochschule.de
-
Contact:
- Tim Havers
- E-mail: thavers@ist-hochschule.de
-
-
Saxony
-
Chemnitz, Saxony, Duitsland, 09126
- Werving
- TU Chemnitz, Sports Medicine and Exercise Therapy
-
Contact:
- Nico Nitzsche, PD Dr. Dr.
- Telefoonnummer: +49 371 531-37326
- E-mail: nico.nitzsche@hsw.tu-chemnitz.de
-
Leipzig, Saxony, Duitsland, 04109
- Werving
- Institute for Applied Training Science (IAT) Leipzig
-
Contact:
- Katharina Dunst, Dr.
- Telefoonnummer: +49 341 4945-184
- E-mail: AnnaKatharina.Dunst@sport-iat.de
-
-
-
-
Central Finland
-
Jyväskylä, Central Finland, Finland, 40014
- Werving
- University of Jyväskylä, Faculty of Sport and Health Sciences
-
Contact:
- Juha Ahtiainen, Prof. Dr.
- Telefoonnummer: +358408053740
- E-mail: juha.ahtiainen@jyu.fi
-
-
-
-
Limerick
-
Limerick, Limerick, Ierland, V94 T9PX
- Werving
- University of Limerick, Department of Physical Education and Sport Sciences (PESS)
-
Contact:
- Brian Carson, Prof.
- Telefoonnummer: +353 (0)61 20 2896
- E-mail: Brian.Carson@ul.ie
-
-
-
-
Madrid
-
Madrid, Madrid, Spanje, 28040
- Werving
- Universidad Politécnica de Madrid, Facultad de Ciencias de la Actividad Física y del Deporte (INEF)
-
Contact:
- Pedro José Benito, Prof. Dr.
- Telefoonnummer: +34 91 336 40 12
- E-mail: pedroj.benito@upm.es
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Ja
Beschrijving
Inclusion Criteria:
- Body Mass Index (BMI) between 20-29 kg/m2
- No structured resistance training performed in the last twelve months.
- Maximum of four sessions per week of recreational or low-to-moderate aerobic endurance activity.
- No history of competitive strength or physique sports.
Exclusion Criteria:
- Diagnosed cardiovascular, pulmonary, metabolic, neuromuscular, or orthopaedic disease that contraindicates exercise.
- Positive response to any question on the PAR-Q 2025 questionnaire.
- Current use of anabolic steroids, creatine, or other substances known to strongly influence muscle hypertrophy.
- Regular engagement in shift work.
- Women who are pregnant or breastfeeding.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Resistance Training Group
Participants in this single-arm cohort will undergo an 8-week standardized, hypertrophy-focused lower-body resistance training program.
|
Standardized training consisting of twice-weekly supervised sessions for 8 weeks.
Each session includes 4 sets of 8-12 repetitions of leg press (or Smith-machine squat) and leg extensions.
Training intensity progresses from an RPE of 6 to voluntary muscular failure starting from week three.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in mid-thigh Muscle Thickness
Tijdsspanne: Baseline and Week 8 (completion of training intervention)
|
Change in mid-thigh muscle thickness (combination of rectus femoris and vastus intermedius) as measured by ultrasound.
|
Baseline and Week 8 (completion of training intervention)
|
|
Change in lateral-thigh Muscle Thickness
Tijdsspanne: Baseline and Week 8 (completion of training intervention)
|
Change in lateral thigh muscle thickness (combination of vastus lateralis and vastus intermedius) as measured by ultrasound.
|
Baseline and Week 8 (completion of training intervention)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Peak Rate of Blood Lactate Accumulation (vLapeak)
Tijdsspanne: Baseline and Week 8 (completion of training intervention)
|
Peak rate of blood lactate accumulation before and after a 10-second all-out seated cycle ergometry test.
Blood lactate will be sampled every minute for 10 minutes post-test to capture the peak value.
|
Baseline and Week 8 (completion of training intervention)
|
|
Change in Vastus Lateralis Muscle Cross-Sectional Area (CSA)
Tijdsspanne: Baseline and Week 8 (completion of training intervention)
|
Change in cross-sectional area of the vastus lateralis at 50% of muscle length measured via ultrasound.
|
Baseline and Week 8 (completion of training intervention)
|
|
Maximal Strength (3RM) for Leg Press
Tijdsspanne: Baseline and Week 8 (completion of training intervention)
|
Change in 3-Repetition Maximum (3RM) for the leg press exercise to assess lower-body multi-joint maximal strength.
|
Baseline and Week 8 (completion of training intervention)
|
|
Maximal Strength (3RM) for Leg Exentsion
Tijdsspanne: Baseline and Week 8 (completion of training intervention)
|
Change in 3-Repetition Maximum (3RM) for the leg extension exercise to assess single-joint quadriceps strength.
|
Baseline and Week 8 (completion of training intervention)
|
|
Change in Relative Abundance of Selected Plasma Metabolites
Tijdsspanne: Baseline and Week 8 (completion of training intervention)
|
Change in the relative concentration of targeted plasma metabolites from baseline to Week 8, as analyzed via mass spectrometry.
|
Baseline and Week 8 (completion of training intervention)
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Ahtiainen JP, Walker S, Peltonen H, Holviala J, Sillanpaa E, Karavirta L, Sallinen J, Mikkola J, Valkeinen H, Mero A, Hulmi JJ, Hakkinen K. Heterogeneity in resistance training-induced muscle strength and mass responses in men and women of different ages. Age (Dordr). 2016 Feb;38(1):10. doi: 10.1007/s11357-015-9870-1. Epub 2016 Jan 15.
- Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 1927 Mar 7;8(6):519-30. doi: 10.1085/jgp.8.6.519. No abstract available.
- Wackerhage H, Kabasakalis A, Seiler S, Heck H. Is the vLamax for Glycolysis What the V O 2 max is for Oxidative Phosphorylation? Sports Med. 2025 Aug;55(8):1853-1866. doi: 10.1007/s40279-025-02259-6. Epub 2025 Jul 17.
- Wackerhage H, Vechetti IJ, Baumert P, Gehlert S, Becker L, Jaspers RT, de Angelis MH. Does a Hypertrophying Muscle Fibre Reprogramme its Metabolism Similar to a Cancer Cell? Sports Med. 2022 Nov;52(11):2569-2578. doi: 10.1007/s40279-022-01676-1. Epub 2022 Apr 23.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
4 mei 2026
Primaire voltooiing (Geschat)
1 december 2026
Studie voltooiing (Geschat)
1 december 2026
Studieregistratiedata
Eerst ingediend
25 juni 2026
Eerst ingediend dat voldeed aan de QC-criteria
20 juli 2026
Eerst geplaatst (Werkelijk)
23 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
23 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
20 juli 2026
Laatst geverifieerd
1 juni 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- HyperLa
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
ONBESLIST
Beschrijving IPD-plan
A formal plan for sharing individual participant data (IPD) with external researchers has not yet been finalized.
The study involves a multicentric international consortium with strict data protection requirements under GDPR.
Data is currently managed centrally via REDCap at the Technical University of Munich.
Requests for data sharing will be considered on a case-by-case basis by the HyperLa Study Group after the primary publication of results, and would require a formal proposal and a signed Data Access or Material Transfer Agreement (MTA)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .